# Resilience subsidiary Ology Bioservices awarded up to $250M DOD contract for botulinum neurotoxin treatment

National Resilience, Inc. announced that its subsidiary Ology Bioservices was awarded a contract valued up to $250 million from the U.S. Department of Defense for manufacturing development of a monoclonal antibody against botulinum neurotoxin.

- Type: Contract
- Announced: 2022-02-09
- Where: Alachua, Florida, United States
- Value: $250.0M
- Status: announced
- Products: monoclonal antibody for botulinum neurotoxin
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [National Resilience](https://endata.com/companies/60934.md)
- [Ology Bioservices](https://endata.com/companies/60935.md)
- [U.S. Department of Defense](https://endata.com/companies/4836.md) (customer)

## Sources

- [biospace.com](https://www.biospace.com/resilience-subsidiary-ology-bioservices-awarded-contract-worth-up-to-250-million-from-u-s-department-of-defense-for-botulinum-neurotoxin-treatment), 2022-02-09: "We are proud to support the Department of Defense develop this important medicine to protect the warfighter from exposure to botulinum toxins."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.